Deregulation

	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X
1	PA-01 Bob Brady (D)	PA-02 Dwight Evans (D)	PA-03 Mike Kelly (R)	PA-04 Scott Perry (R)	PA-05 Glenn Thompson (R)	PA-06 Ryan Costello (R)	PA-07 Patrick Meehan (vacant R)	PA-08 Brian Fitzpatrick (R)	PA-09 Bill Shuster (R)	PA-10 Tom Marino (R)	PA-11 Lou Barletta (R)	PA-12 Keith Rothfus (R)	PA-13 Brendan Boyle (D)	PA-14 Michael Doyle (D)	PA-15 Charlie Dent (vacant R)	PA-16 Lloyd Smucker (r)	PA-17 Matthew Cartwright (D)	PA-18 Tim Murphy (replaced R)	PA-18 Conor Lamb (D)		Deregulation
2																				Link to Bill Details	Topic	Date	Vote result

3	No	No	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	X	Yes	No	No	Yes	Yes	No	Yes	X	H.R. 985	Makes it harder to file class action lawsuits	03-09-17	220-201
4	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	X	Yes	Yes	No	No	Yes	Yes	No	Yes	X	H.R. 10	Partial dismantling of Dodd-Frank, possible defunding of CFPB	06-08-17	233-186
5	No	No	Yes	Yes	Yes	No	No	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	No	Yes	X	H.R. 1215	Limits ability to file malpractice lawsuits for recipients of Medicare, Medicaid, ACA	06-28-17	218-210
6	No	No	Yes	Yes	Yes	X	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	Yes	X	H.J. Res. 111	Stopping the CFPB from ending forced arbitration practices by financial corporations	07-25-17	230-190
7	X	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	X	X	H.R. 3441	Limits liability for corporations who franchise and sub-contract	11-07-17	242-181
8	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	X	No	Yes	Yes	No	X	X	H.R. 3299	lets payday lenders and other high-interest loan providers bypass usury laws in states	02-14-18	245-181
9	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	X	X	H.R. 4296	lets big banks increase their borrowing and reduce the private capital held to protect the public against megabank failures	02-27-18	245-169
10	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	X	X	H.R. 4607	chips away at the CFPB ability to work for consumers, by adding more review burdens	03-06-18	264-143
11	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	X	X	H.R. 1116	Forces government regulators (all areas) to report on new rules implemented in the last seven years and tailor them to limit burdens on industry	03-14-18	247-169
12	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	X	X	H.R. 4263	Gives exemptions from reporting requirements that used to go to small, community banks to larger banks	03-15-18	246-170
13	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	X	X	H.R. 4545	adds a new layer of appellate process to the CFPB so banks can appeal supervisory decisions	03-15-18	283-133
14	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	X	Yes	No	Yes	Yes	Yes	Yes	X	X	H.R. 4566	exempts brokerage and investment firms (NBFIs - non bank financial institutions) from more than 1 stress test per year	03-20-18	395-19
15	No	No	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	X	X	H.R. 5247	Removing FDA oversight into access to trial drugs for the terminally ill	03-21-18	267-149
16	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	X	X	H.R. 4293	reduces the number of Dodd-Frank mandated stress tests for banks	04-11-18	245-174
17	X	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	X	Yes	H.R. 4790	grants the Federal Reserve excusive rulemaking authority over the Volcker rule, exempts some banks	04-13-18	300-104
18	No	No	Yes	Yes	Yes	Yes	X	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	X	No	S.J. Res. 57	Removes auto-lenders from CFPB anti-discriminatory oversight	05-08-18	234-175
19	No	No	Yes	Yes	Yes	Yes	X	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	X	No	H.R. 5645	Reduces federal oversight of big corporate mergers, and forces the FTC to oppose mergers through the courts (as opposed to administrative review)	05-09-18	230-185
20	No	No	Yes	Yes	Yes	Yes	X	Yes	Yes	Yes	Yes	Yes	No	No	X	Yes	No	X	No	S. 2155	Changes regulatory oversight for mid-size ($50-$250 billion) banks and exempts them from the Viocker Rule	05-22-18	258-159
21	No	No	Yes	Yes	Yes	Yes	X	Yes	Yes	Yes	Yes	Yes	No	No	X	Yes	No	X	No	S. 204	Removing FDA oversight into access to trial drugs for the terminally ill	05-22-18	250-169